10.21147/j.issn.1000-9604.2020.04.06
Dose-dense paclitaxel plus carboplatin vs.epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
32
This work was supported by National Key Research and Development Program of China ;and Chinese Academy of Medical Science Initiative for Innovative Medicine
2020-10-14(万方平台首次上网日期,不代表论文的发表时间)
共12页
485-496